Proteinase Activated Receptor 4 in the Jejunum of Healthy Horses and of Horses With Epiploic Hernia

Carlotta Lambertini*, Cristiano Bombardi, Augusta Zannoni, Chiara Bernardini, Francesco Dondi, Maria Morini, Riccardo Rinnovati, Alessandro Spadari and Noemi Romagnoli

Department of Veterinary Medical Sciences, University of Bologna, Ozzano Dell’Emilia, Italy

Proteinase activated receptor 4 (PAR4) in the gastrointestinal tract is involved in the regulation of inflammation and pain pathways. The aim of the present study was to evaluate the distribution and expression of PAR4 in the jejunum of healthy horses and in the pathologic tracts from horses undergoing surgery for herniation of the small intestine through the epiploic foramen. Eight healthy horses (Group H) and eight horses with epiploic hernia (Group EH) were included; the jejunum samples were collected at the slaughter or intraoperatively after enterectomy, respectively. To evaluate PAR4 expression in sections of the jejunum, immunofluorescence, western blot and quantitative polymerase chain reaction (qRT-PCR) were performed. Immunohistochemistry of PAR4 in the jejunum of the healthy horses showed that receptors are predominantly expressed in the immune cell population scattered throughout the lamina propria of the mucosa and in the submucosa. Quantitative PCR data demonstrated that PAR4 mRNA was detectable in all of the samples analyzed without any difference between the H and the EH groups, however the PAR4 protein level was significantly lower in the jejunums of the EH horses. In the Group EH horses, PAR4 immunoreactivity was mainly expressed in the mast cells and was extensively distributed in the sierosa. In the lamina propria of mucosa of Group EH, leukocytes were less abundant than in Group H. In this study, the distribution and expression of PAR4 in the jejunums of the healthy horses and in those with spontaneous occurring epiploic hernia was demonstrated.

Keywords: epiploic foramen hernia, equine, jejunum, mast cells, proteinase-activated receptor 4

INTRODUCTION

In horses, herniation of the small intestine through the epiploic foramen (epiploic hernia-EH) is a common cause of strangulation of the small intestine and has been reported from 3.5 to 5% of horses with colic undergoing surgery (4, 5). More frequently, compression within the foramen or anatomical displacement cause vein occlusion with subsequent tissue congestion, oedema, hemorrhagic infarction, and inflammation (6). Moreover, when artery compression develops, ischemic lesions also appear (7). Tissue necrosis can advance up to one meter involving the afferent and efferent intestinal loops not involved in the hernia (1). The surgical treatment of an EH consists of reducing the herniation and resection of the abnormal intestinal tract (7). However, reperfusion of the ischemic intestine might results in reperfusion injury characterized by the aggravation of the aforementioned lesions (2, 8).
Several studies in humans and in animal models have investigated the role of proteinase activated receptors (PARs) in the pathophysiology of intestinal diseases (9–12). Proteinase activated receptors constitute a receptor subfamily belonging to the largest group of G-protein coupled receptors (13–16). In humans, PARs 1 to 4 have been identified throughout the gastrointestinal tract where they are exposed to high levels of proteinases, digestive proteinases, and those produced by enteric pathogens, and are therefore relevant in the regulation of several mechanisms (15, 17–19). In addition the expression of proteases increases significantly during inflammatory processes (17). The proteases interact with PARs by cleaving the extracellular N-terminus portion; the tethered ligand in this way is exposed binds to a second extracellular ring of the receptor thereby activating the receptor itself (9). Proteinase activated receptor 4 is activated by trypsin, cathepsin G and activated factor X and is considered particularly involved in the regulation of inflammation, nociception, sensitization, and pain pathways (20–23). In humans, authors are investigating the role of PAR2 and PAR4 in the pathogenesis of irritable bowel syndrome and in the modulation of hypersensitivity associated with persistent tissue inflammation (10, 12). The expression and distribution of PAR4 in the equine small intestine has not yet been investigated.

The aim of the present study was to evaluate the distribution and expression of PAR4 in the jejunums of healthy horses and in the ischemic tracts collected from horses undergoing surgery for colic of the small intestine. Therefore, horses with herniation of the small intestine through the epiploic foramen were considered as model of inflammation and strangulating obstruction of the small intestine.

To evaluate PAR4 expression in sections of the jejunum, immunofluorescence, and gene and protein expression studies were carried out.

**MATERIALS AND METHODS**

**Animals**

The study was approved by the Ethical Scientific Committee for experimental animals of the University of Bologna (Prot. n 15-IX/, 08/05/2012). Eight healthy horses (group H) and eight horses with EH (group EH) were included in the study.

In Group H, eight adult food-producing Standardbred horses sent to slaughter were included. These horses were considered healthy based on history, and physical and clinicopathological examination, and on the basis of gross and histological evaluations of the jejunum. There were five females and three geldings of different breeds; their median age was 10.5 years (range 2–20). In Group EH, eight adult sport Standardbred horses (three females and five geldings) admitted to the Veterinary teaching hospital (VTH) of the Department of Veterinary Medical Sciences for colic syndrome and in which an exploratory laparotomy confirmed a clinical diagnosis of herniation of the small intestine through the epiploic foramen were included. All patients underwent an enterectomy of the jejunum followed by anastomoses within 2–18 h from admission. At the end of the surgery, horses with colic were followed by the VTH and discharged within 7–10 days from admission.

**Blood Sampling and Analysis**

In the Group H horses, blood samples were collected from the jugular vein at exsanguination. In the Group EH horses, blood samples were collected within 30 min from admission from the jugular vein by venipuncture. Blood samples were collected in K3EDTA, citrate and clot activator. In detail, a complete blood count was carried out including: hematocrit value, hemoglobin concentration, erythrocyte indices, platelet count, and white blood cells and differential white blood cells counts. The chemical profile included aspartate transaminase, lactate dehydrogenase, creatine kinase, creatinin, urea, glucose, lactate, total bilirubin, γ-glutamyl transferase, total protein, total calcium, phosphorus, sodium, potassium, and chloride. The coagulation profile included D-dimers and antithrombin. The acute-phase protein profile included serum amyloid A, haptoglobin, ferritin, fibrinogen, total iron, transferrin (such as total iron binding capacity), and albumin. The samples collected were processed and analyzed within one hour or stored at −80°C. The blood analysis were carried out using an automated hematology system (ADVIA 2120, Siemens Healthcare Diagnostics, Tarrytown, NY, USA) and an automated chemical analyzer (AU 400, Olympus/Beckman Coulter, Brea, CA, USA).

**Sampling and Morphological Evaluations**

In the group H horses, samples of the jejunum were collected at the evisceration phase of the slaughter. At the time of collection, samples were examined internally and externally to exclude gross intestinal lesions. In the group EH horses, the abnormal tract of the jejunum was resected intraoperatively and a jejuno-jejunal or jejuno-ileal anastomosis was performed by an experienced surgeon. The ischemic intestinal tract removed was used for research purposes with the informed consent of the owners. All the samples collected for the analysis were obtained in the center of the abnormal removed intestine.

After collection, a part of the jejunum was dissected and washed with phosphate buffered saline (PBS) (Gibco-Invitrogen, Paisley, UK). The intestinal mucosa was then scraped with two glass slides; the samples were frozen in liquid nitrogen and stored at −80°C until RNA and protein extraction were carried out. In addition, full thickness bioptic samples from the jejunum were carried out, rinsed in PBS and then immediately stored in 10% neutral buffered formalin and 4% paraformaldehyde.

Histological evaluations were carried out on samples fixed in 10% neutral buffered formalin, embedded in paraffin within 24–48 h, cut into 5 μm thick sections and stained with hematoxylin and eosin. For group H, the histological samples were also evaluated according to an inflammation score using a semiquantitative estimation of the inflammatory cells in the mucosa and submucosa, as described by Packer et al. (24).

Only those horses in which the intestinal specimens were within the normal range were included in the study. In addition, for samples of both groups, tissue viability was determined based on

**Abbreviations:** EH, Epiploic hernia; PAR, Proteinase activated receptor; PBS, Phosphate buffered saline.
the morphological changes present in the tissue sections using light microscopy and was based on a scoring system previously described by Van Hoogmoed et al. (25).

**Immunohistochemistry Experiments**

In both groups, samples for immunohistochemical evaluation were prepared as previously described (26) to obtain 14–15 µm thick cryostat serial longitudinal sections, which were mounted on polylysine-coated slides and stored at −80°C until immunohistochemical evaluations were carried out. The sections were then rehydrated three times with PBS (0.02 M, pH 7.4) before beginning the immunostaining. To block non-specific binding, the sections were incubated in a solution containing 10% normal donkey serum (Colorado Serum Co, Denver, CO, USA) and 0.5% Triton X-100 (Merck, Darmstadt, Germany) in PBS for an hour at room temperature in a humid chamber. An hour later the sections were incubated in primary antibody goat anti-PAR4 (1:100, Santa Cruz Biotechnology Cat# sc-8464, RRID:AB_653835) diluted in antibody diluent (1.8% NaCl in 0.01 M sodium phosphate buffer containing 0.1% sodium azide), 1% normal donkey serum and 0.5% Triton for 24 h at room temperature in an humid chamber. The day after, the sections were washed with PBS three times every 10 min and incubated in a solution containing a secondary antibody donkey anti-goat (1:400, Alexa Fluor 594, Thermo Fisher Scientific, Waltham, MA, USA) and 0.5% Triton diluted in PBS in humid chamber. Finally, the slides were washed three times with PBS and were then cover slipped with buffered glycerol (pH 8.6).

Thereafter double immunohistochemistry evaluations were performed adding different primary and secondary antibodies to the solution previously described. The sections used for mast cells assessments were incubated for 24 h at room temperature with a primary antibody solution containing the antibody rabbit anti-tryptase (1:80 Cloud clone corp, Huston, TX, USA, Cat# A-11058, RRID:AB_2534105), 1% normal donkey serum, 0.5% Triton diluted in PBS in humid chamber. Finally, the slides were washed three times with PBS and were then cover slipped with buffered glycerol (pH 8.6).

**RNA Isolation and Quantitative Real Time PCR (qRT-PCR) for PAR4**

The RNA extraction was performed on samples collected from each horse from the group H (n = 8) and the group EH (n = 8); RNA extraction and qPCR analysis were essentially carried out as reported by a previous study (26). Briefly, samples of scraped jejunum mucosa were pulverized using a mortar and pestle and liquid nitrogen; 25 µg of each sample were then lysed in Tissue Lyser TL (50 Hz for 5 min, 2 beads diameter 2 mm, QIAGEN, Hilden, Germany). The total RNA extraction was carried out using the NucleoSpin RNA II (Macherey Nagel, Duren, Germany) instructions. The RNA was spectrophotometrically quantified (A260 nm), and its quality was determined by gel electrophoresis on 1% agarose. Subsequently, 1 µg of RNA was reverse-transcribed to cDNA using an iScript cDNA Synthesis Kit (Bio-Rad Laboratories Inc., Hercules, CA, USA) in a final volume of 20 µl. Real-time quantitative PCR was carried out using a CFX 96 Real Time System (Bio-RAD Laboratories Inc.) and iTaq Universal SYBR Green Supermix (Bio-RAD Laboratories Inc.). All samples were analyzed in duplicate (10 µl/well).

The PAR4 and reference genes (GAPDH; HPRT and ß-Actin) primer sequences, expected PCR product lengths and the accession numbers in the National Center of Biotechnology Information (NCBI) database are shown in Table 1.

The expression level of the PAR4 gene was determined using the 2$^{-\Delta\Delta C_T}$ method (27) in which $\Delta C_T = (C_T$ PAR4 - C_T mean ref. genes) and $\Delta \Delta C_T = \Delta C_T$ EH-group - $\Delta C_T$ H-group.

**PAR4 Western Blotting**

One sample collected from each horse of the group H (n = 8) and of the group EH (n = 8) was used for the western blot analysis.

Fifty mg of pulverized jejunal mucosa were lysed with sodium dodecyl sulfate solution (Tris-HCl 50 mM pH 6.8; sodium dodecyl sulfate 2%; glycerol 5%; 500 µl) supplemented with a protease inhibitor cocktail (P8340, Sigma-Aldrich, Co, St. Louis, MO, USA) in Tissue Lyser TL (50 Hz for 2 min, 3 beads diameter 2 mm). The protein content of the samples was determined using a Protein Assay Kit (TP0300, Sigma-Aldrich, Co, St. Louis, MO, USA). Aliquots containing 20 µg of protein were separated using Bolt 4–12% bis-Tris Plus (Life Technologies Ltd, Paisley, UK) for 55 min at 165 V. The proteins were then electrophoretically transferred onto a nitrocellulose membrane using the Turbo Blot System (Bio-Rad Laboratories Inc., Hercules, CA, USA). The blots were washed in PBS, and protein transfer was checked using 0.2% Ponceau Red staining. Non-specific binding on nitrocellulose membranes was blocked with 5% milk in PBS-T20 (phosphate buffer saline-0.1% Tween-20) for 1 h at room temperature. The membranes were then
incubated overnight at 4°C with a 1:200 dilution of primary antibody goat anti-PAR4 (sc-8464, Santa Cruz Biotechnology, Dallas, TX, USA) in Tris Buffered Saline-T20 (TBS-T20 20 mM Tris-HCl, pH 7.4, 500 mM NaCl, 0.1% T-20). After several washings with PBS-T20, the membranes were incubated with the secondary donkey anti-goat IgG-HRP antibody (sc-2020, Santa Cruz Biotechnology, Cat# sc-2020, RRID:AB_631728, 1:7000 dilution in TBS-T20, 1 h at RT). The Western blots were developed using chemiluminescent substrate (Clarity ECL Western Blot Substrate, Bio-Rad Laboratories Inc., Hercules, CA, USA) with LabImage Software (Bio-Rad Laboratories Inc, Hercules, CA, USA).

In order to normalize the PAR4 data on the reference protein, the membranes were washed for 5 min in water, then for 5 min in 0.2 M NaOH and then washed again in water and reprobed for the reference α-tubulin (1:500; cod.TU-01 Thermo Scientific, Waltham, MA, USA). The relative PAR4 protein content was normalized on the mean value of the reference protein (α-tubulin) and was expressed as arbitrary units.

**Statistical Analysis**

Descriptive statistic was used to evaluate the clinicopathological data, and the reference intervals of our laboratory were used for comparison. The PAR4 protein and mRNA in the jejunum were compared between the H and the EH groups using a student’s t-test. p < 0.05 was considered statistically significant. The protein and mRNA analyses were carried out using GraphPad Prism software (La Jolla, CA, USA).

**RESULTS**

**Clinicopathological and Histopathological Evaluation**

In group H horses the clinicopathological results were within the normal reference range. In group EH horses an increase in Serum amyloid A (median 149 μg/mL; reference range: 1–10 μg/mL), creatinine (median 2.15 mg/dL; reference range: 0.90–1.50 mg/dL) and d-dimer (median 2.90 μg/mL; reference range: 0.20–0.48 μg/mL) concentrations were observed. These results have already been published in a previous paper (28). At histological evaluation of the samples collected from the horses in group H, the median score was 2 (range 0–3). Twenty four samples were collected from the horses in group EH; in all of them the median score was 12 (range 6–40). In terms of hemorrhage and edema score (25) in this latter group, 14 samples had lesions of mild severity, while 10 samples had extensive disruption of structural integrity.

In the samples from group H, the quantitative data regarding the inflammatory cell populations was within the normal range as previously defined by Packer et al. (24).

**Immunohistochemistry**

Proteinase activated receptor 4 immunohistochemistry in the jejunums of the healthy horses showed a weak receptor distribution, mainly in immune cell population, especially lymphocytes (Figure 1). These cells were predominant in the lamina propria of the mucosa and in the submucosa. In the submucosa, lymphocytes were observed only in a diffuse form. Proteinase activated receptor 4 immunoreactivity was not observed in the enterocytes and intestinal glands; in addition, the smooth muscle cells were negative with the exception of a few elements having weak immunoreactivity. In the superficial epithelium, lymphocytes with weak staining were observed. Some mast cells immunostained for tryptase were located in the submucosa (Figures 2A–C) and in the serosa (Figures 2D–F).

In group-EH horses, lymphocytes of the lamina propria of mucosa exhibited an intensity of immunofluorescence slightly lower than in group H. In the submucosa and superficial epithelium some weakly-immunostained lymphocytes could be observed. In this group, PAR4 immunoreactivity was mainly expressed in the mast cells, immunostained for tryptase that were extensively distributed in the serosa (Figures 2G–L). The intensity of the immunofluorescence of the mast cells was similar in the two groups. Immunoreactivity was not observed in the submucosal and myenteric plexi either in Group H or in Group EH.

**Quantitative Real-time PCR for PAR4 in the Equine Jejunum**

Quantitative PCR data demonstrated that PAR4 mRNA was detectable in all of the samples analyzed.
Lambertini et al. PAR4 in the Equine Gut

**FIGURE 1** | Lymphocytes immunoreactive for the PAR4 (PAR4-IR) in the lamina propria of the horse jejunum of group H (A–F) and group EH (G–L). (A–C) and (G–I): Anti-CD79 in green (LB), PAR4-IR in red (P) and co-localization of PAR4 and CD79 in B lymphocytes in yellow (LB+P). (D–F) and (J–L): Anti-CD3 in green (LT), PAR4-IR in red (P) and co-localization of PAR4 and CD3 in T lymphocytes in yellow (LT+P). Arrowheads indicate double immunolabeled lymphocytes. Scale bar = 20 µm in L (applied to A–L).

No significant statistical difference of its expression in the jejunum tracts was observed between the groups EH ($2^{-\Delta\text{Ct}} = 0.49$) and H ($2^{-\Delta\text{Ct}} = 1$). The range of relative expression (lower and upper range), represented as error bars, was: 0.574–1.348 for H group and 0.365–1.41 for EH group (**Figure 3**).

**PAR4 Western Blotting in the Equine Jejunum**
Under denaturing gel electrophoresis conditions (SDS–PAGE), western blots of the mucosa of the equine jejunum tracts showed a clear band of the expected molecular weight for PAR4 (∼38 kDa) (**Figures 4A,B**). The PAR4 protein level was statistically lower in the jejunum tracts of the group EH ($p < 0.05$) (**Figure 4C**).

**DISCUSSION**
In the present study, the distribution and expression of PAR4 in the jejunum of healthy horses and in those with spontaneous occurring epiploic hernia has been demonstrated for the first time.

The expression and distribution of PAR4 has been investigated in humans and in mice (10, 12, 17, 19, 20, 22). In details, PAR4 mRNA expression has been identified in the small intestine and in
the colon. In the colon the immunohistochemistry demonstrated the expression of PAR4 at the epithelium surface and crypts, in the submucosa and in the majority of mast cells (10, 12, 17). In the present study, immunoreactivity was not observed in the enterocytes and the submucosal cells, but mainly in the immune cell population identified as mast cells and B and T lymphocytes. 

The expression of PAR4 in B lymphocytes has already been described in the human liver but authors did not find PAR4 mRNA in human circulating lymphocytes (29, 30).

The expression of PAR4 in mast cells is in accordance with previous studies in humans (10, 12). In particular, in human patients the inflammatory bowel disease resulted in a reduced expression of PAR4 in the colonic mast cells supporting its role in the modulation of visceral nociception (10, 12). Conversely, the results of the present study showed that the expression of PAR4 on mast cells in the jejunum did not change between healthy horses and those with epiploic hernia. However, we could not exclude that the lack of difference in the expression of PAR4 on these cells between the two groups is associated with the acute onset of the inflammatory process affecting the horses with epiploic hernia. The mast cells, in the peripheral tissues, modulate the nociceptive pathways, especially those of inflammatory origin. In fact, by means of mediators and cytokines release (tryptase and interleukin 1β) they activate other immune cells (neutrophils, macrophages and T cells) and amplify the inflammatory response (3, 31, 32). The mast cells in the intestinal tract seem to be particularly involved in the regulation of visceral hypersensitivity through PAR4 (3, 33, 34). In fact,
administration of a synthetic PAR\textsubscript{4} activating peptide decreased the nociceptive response induced by visceral stimulation and inhibited the colonic hypersensitivity induced by the previous activation of the PAR\textsubscript{3} (22). The same authors found also that PAR\textsubscript{4}-deficient mice showed enhanced pain behaviors (licking of abdomen, stretching and abdominal retraction) in response to colorectal stimuli as compared with wild type animals (22). In addition, the presence of PAR\textsubscript{4} has been demonstrated in the dorsal root ganglia neurons where it reduces their excitability (36). These findings confirm the role of PAR\textsubscript{4} not only in the modulation of nociception but also in the regulation of pain pathways.

A simultaneous activation of both PAR\textsubscript{2} and PAR\textsubscript{4} in the jejunum of horses with epiploic hernia and their involvement in the modulation of the inflammatory process associated with this pathological condition can’t be excluded. In the equine bowel, the PAR\textsubscript{3} expression has already been described either in healthy animals or in those with spontaneous occurring EH (26, 28). The results of these previous studies support an activation of the PAR\textsubscript{2} during the ischemic process associated with intestinal herniation (28). Herein, the lower protein level for PAR\textsubscript{4} found in the jejunoctums of horses with epiploic hernias, as compared with samples collected from healthy horses, supports the activation of PAR\textsubscript{4} (37, 38). In fact, the activation of PARs by proteinases, is characterized by an irreversible proteolytic cleavage of the N-terminal domain of the receptor determining a conformational change of the receptors itself which is then internalized to reach intracellular effectors (37). After internalization PARs are degraded by lysosomes or recycled by endosomes (37). The degradation of the receptor can explain the decreased protein level observed in our study.

Proteinase activated receptors have been described also in the enteric nervous system where they are activated by proteinases, and they induce excitatory neuronal responses (18, 39). In the small intestine of the guinea pig, authors have found that submucosal plexus neurons express PAR\textsubscript{2} and that a large proportion of myenteric neurons express PAR\textsubscript{1} and PAR\textsubscript{2} (40, 41). However, Mueller et al. (18) also found that stimulation with a PAR\textsubscript{4} selective peptide induced a spike discharge in human and guinea pig submucosal neurons, even if the response was weaker and involved fewer neurons when compared with that obtained after the application of the PAR\textsubscript{3} selective peptide. In horses, the submucosal plexus neurons and the myenteric plexus neurons expressed PAR\textsubscript{2} (26, 28) but, in the present study, immunostaining for PAR\textsubscript{4} was not observed in these cells. Therefore, based on the lack of expression of PAR\textsubscript{4} in the enteric nervous system’s neurons, it can be hypothesized that, in equine jejunoctums, this receptor is not involved in the regulation of neurotransmission in both healthy horses and in horses with epiploic hernia. Instead, PAR\textsubscript{2} could be involved in the alteration of neurotransmission and intestinal motility during an inflammatory process as previously described in animal models (42). However, to date, there are no data concerning the role of PAR activation in the enteric nervous system in horses.

The increase in the SAA and plasmatic D-dimer and creatinine concentrations above the reference range are in accordance with previous studies in colic horses (43–46). In
fact, the intestinal inflammatory process results in an increased concentration of acute phase protein like SAA (44, 47). In details, the increase of SAA concentration better correlates with the presence of inflammatory lesions compared with strangulating obstruction and in a previous study only the 21% of horses with pathologies involving the small intestine had an increase of SAA concentration above the reference range (44). In addition, disseminated intravascular coagulation is a complication related with acute gastrointestinal tract disease in horses. Increased plasma D-Dimer concentration and creatinine concentration have been previously reported in colic horses with coagulation disorders as marker of coagulopathies and subsequent organ damage respectively (43, 45, 48). However, clinical disseminated intravascular coagulation was not observed in the patients of the present study. The relationship between PAR4 expression and SAA was not evaluated. Further studies are needed to evaluate the application of the evaluation of PAR4 expression with SAA as a diagnostic and prognostic tool in horses with epiploic hernia.

In conclusion, these preliminary results support PAR4 expression in the equine jejunum and its potential activation during small intestinal herniation though the epiploic foramen. On the basis of previous studies, the local administration of the PAR4 activating peptide could be taken into consideration as a novel therapeutic approach for the treatment of inflammation and pain in horses with gastrointestinal disorders. In addition, as previously demonstrated in rodents, in equine species PAR4 activation might be involved in the modulation of visceral hypersensitivity associated with the PAR2 activation. However, the expression of PAR4 in the other intestinal tracts of the horse has still to be clarified and additional studies are needed to clearly define the role of PAR4 in the equine intestine.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation, to any qualified researcher.

ETHICS STATEMENT

The study was approved by the Ethical Scientific Committee for experimental animals of the University of Bologna (Prot. n 15-IX, 08/05/2012). Written informed consent was obtained from the owners for the participation of their animals in this study.

AUTHOR CONTRIBUTIONS

CL, CBo, AZ, CBe, FD, and MM conducted data management, analysis, and interpretation of results. RR, AS, and NR performed samples collection. CL wrote the first draft of the manuscript. CBo and AZ wrote sections of the manuscript. NR and AZ contributed in conception and design of the study. All authors contributed to manuscript revision and approved the submitted version.

FUNDING

This study was founded with grants provided by the University of Bologna; RFO-2018.

REFERENCES

1. Youssef HA, Ali MM, Kuraa HMM. Effect of small intestine strangulation obstruction on clinical and histopathological parameters. An experimental study in donkeys. Vet Res Forum. (2011) 2:75–86.
2. Wong DM, Moore RM, Brockus CW. Intestinal ischemia-reperfusion injury in horses: pathogenesis and therapeutics. Compend Contin Educ Vet. (2012) 34:ES.
3. Hao Y, Niu H, An S, Wang M, Wang Z. Downregulation of iNOS, IL-1β, and P2X7 expression in mast cells via activation of PAR4 contributes to the inhibition of visceral hyperalgesia in rats. J Immunol Res. (2018) 2018:3256908. doi: 10.1155/2018/3256908
4. Phillips TJ, Walmsley JP. Retrospective analysis of the results of 151 exploratory laparotomies in horses with gastrointestinal disease. Equine Vet J. (1993) 25:427–31. doi: 10.1111/j.2042-3306.1993.tb02895.x
5. Vachon AM, Fischer AT. Small intestinal herniation through the epiploic foramen: 53 cases (1987-1993). Equine Vet J. (1995) 27:373–80. doi: 10.1111/j.2042-3306.1995.tb04073.x
6. Sullins KE, Stashak TS, Mero KN. Pathologic changes associated with induced small intestinal strangulation obstruction and nonstrangulating infarction in horses. Am J Vet Res. (1985) 46:913–16.
7. Freeman DE. Small intestine. In: Auer JA, Stick JA, editor. Equine Surgery, fourth ed. St. Louis, MI: Elsevier (2012). p. 416–53. doi: 10.1016/B978-1-4377-0867-7.00036-3
8. Faleiros RR, Alves GES, Santos RL, Marques Junior AP, Macoris DG. Experimental ischemia and reperfusion in equine small colon. Arq Bras Med Vet Zootec. (2001) 53:341–50. doi: 10.1590/S0102-0935200100300012
9. Bradesi S. PAR4: a new role in the modulation of visceral nociception. Neurogastroenterol Motil. (2009) 21:1129–32. doi: 10.1111/j.1365-2982.2009.01373.x
10. Han W, Wang Z, Lu X, Guo C. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome. Neurogastroenterol Motil. (2012) 24:113–9 doi: 10.1111/j.1365-2982.2011.01841.x
11. Mulè F, Pizzuti R, Capparelli A, Vergnolle N. Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon. Gut. (2004) 53:229–34. doi: 10.1136/gut.2003.012899
12. Zhao JH, Dong L, Shi HT, Wang ZY, Shi HY, Ding H. The expression of protease-activated receptor 2 and 4 in the colon of irritable bowel syndrome patients. Dig Dis Sci. (2012) 57:58–64. doi: 10.1007/s10620-011-1827-3
13. Antalík TM, Shea-Donohue T, Vogel SN, Sears C, Fasano A. Mechanisms of disease: protease functions in intestinal mucosal pathobiology. Nat Clin Pract Gastronenterol Hepatol. (2007) 4:393–402. doi: 10.1038/nccp-gastrothe.0846
14. Fender AC, Rauch BH, Geisler T, Schrö R. Protease-activated receptor PAR-4: an inducible switch between thrombosis and vascular inflammation? Thromb Haemost. (2017) 117:2013–25. doi: 10.1160/TH17-03-0219
15. Vergnolle N. Protease-activated receptors (PARs) in infection and inflammation in the gut. Int J Biochem Cell Biol. (2008) 40:1219–27. doi: 10.1016/j.biocell.2008.01.016
16. Vergnolle N. Protease inhibition as new therapeutic strategy for GI diseases. Gut. (2016) 65:1215–24. doi: 10.1136/gutjnl-2015-309147
17. Dabek M, Ferrier L, Roka R, Gecse K, Annahazi A, Moreau J, et al. Luminal cathespin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol. (2009) 175:207–14. doi: 10.2353/ajpath.2009.080986
cytokines in irritable bowel syndrome. *Gut.* (2017) 66:2040–2. doi: 10.1136/gutjnl-2016-313504

26. Karanja R, Spreadbury I, Bautista-Cruz F, Tsang ME, Vannier S. Activation of protease-activated receptor-4 inhibits the intrinsic excitability of colonic dorsal root ganglia neurons. *Neurogastroenterol Motil.* (2009) 21:1218–21. doi: 10.1111/j.1365-2982.2009.01353.x

27. French SL, Hamilton JR. Protease-activated receptor 4: from structure to function and back again. *Br J Pharmacol.* (2016) 173:2952–65. doi: 10.1111/bph.13455

28. Zuo Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. *Pain.* (2003) 105:467–79. doi: 10.1016/S0304-3959(03)00261-6

29. Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology.* (2004) 126:693–702. doi: 10.1053/j.gastro.2003.11.055

30. Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology.* (2007) 132:26–37. doi: 10.1053/j.gastro.2006.11.039

31. Héron A, Dubayle D. A focus on mast cells and pain. *Cell Immunol.* (2013) 264:1–7. doi: 10.1016/j.cellimmunol.2013.09.018

32. Zuo Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. *Pain.* (2003) 105:467–79. doi: 10.1016/S0304-3959(03)00261-6

33. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology.* (2004) 126:693–702. doi: 10.1053/j.gastro.2003.11.055

34. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology.* (2007) 132:26–37. doi: 10.1053/j.gastro.2006.11.039

35. An S, Zong G, Wang Z, Shi J, Du H, Hu J. Activation of protease-activated receptor 4 of mast cells could downregulate proinflammatory cytokines in irritable bowel syndrome. *Gut.* (2017) 66:2040–2. doi: 10.1136/gutjnl-2016-313504

36. Karanja R, Spreadbury I, Bautista-Cruz F, Tsang ME, Vannier S. Activation of protease-activated receptor-4 inhibits the intrinsic excitability of colonic dorsal root ganglia neurons. *Neurogastroenterol Motil.* (2009) 21:1218–21. doi: 10.1111/j.1365-2982.2009.01353.x

37. French SL, Hamilton JR. Protease-activated receptor 4: from structure to function and back again. *Br J Pharmacol.* (2016) 173:2952–65. doi: 10.1111/bph.13455

38. Zuo Y, Perkins NM, Tracey DJ, Geczy CL. Inflammation and hyperalgesia induced by nerve injury in the rat: a key role of mast cells. *Pain.* (2003) 105:467–79. doi: 10.1016/S0304-3959(03)00261-6

39. Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. *Gastroenterology.* (2004) 126:693–702. doi: 10.1053/j.gastro.2003.11.055

40. Stanghellini V, De Giorgio R, Cremon C, Di Nardo G, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. *Gastroenterology.* (2007) 132:26–37. doi: 10.1053/j.gastro.2006.11.039

41. Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EE, et al. Mast cell tryptase-activated receptor-2 induce hyperexcitability of guinea-pig submucosal neurons. *J Physiol.* (2003) 547:31–42. doi: 10.1113/jphysiol.2002.032011

42. Linden DR, Manning BP, Bunnell NW, Masew GM. Agonists of proteinase-activated receptor 2 excite guinea pig ileal myenteric neurons. *Eur J Pharmacol.* (2001) 431:311–14. doi: 10.1016/S0014-2999(01)01447-9

43. Dolente BA, Wilkins PA, Boston RC. Clinicopathological evidence of disseminated intravascular coagulation in horses with acute colitis. *J Am Vet Med Assoc.* (2002) 220:1034–8. doi: 10.2460/javma.2002.220.1034

44. Vandenplas ML, Moore JN, Barton MH, Roussel AJ, Cohen ND. Concentrations of serum amyloid A and lipopolysaccharide-binding protein in horses with colic. *Am J Vet Res.* (2005) 66:1509–16. doi: 10.2460/javma.2005.66.1509

45. El-Zahar H, Bayoumi Y, Salahy S, Gheblen H, Shety T. Plasma d-dimer concentration in horses with colic. *J Vet Intern Med.* (2003) 17:245–51. doi: 10.1111/j.1939-1676.2003.tb00415.x